ID   BG1
AC   CVCL_6570
SY   BG-1; BG-I; Bowman Gray-1; BG-1 FR
DR   BTO; BTO:0000177
DR   BioSample; SAMN03151838
DR   ChEMBL-Cells; CHEMBL3307815
DR   ChEMBL-Targets; CHEMBL613537
DR   Cosmic; 844351
DR   Cosmic; 1709248
DR   GEO; GSM851910
DR   Millipore; SCC415
DR   PubChem_Cell_line; CVCL_6570
DR   Wikidata; Q54796229
RX   PubMed=2910432;
RX   PubMed=9698466;
RX   PubMed=9769151;
RX   PubMed=22328975;
RX   PubMed=22710073;
RX   PubMed=25321415;
CC   Problematic cell line: Partially contaminated. Some stocks are contaminated by MCF-7 (PubMed=22710073; PubMed=25321415).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00456.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): Millipore; PubMed=25321415
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 10
ST   D16S539: 9,11
ST   D18S51: 12,15
ST   D19S433: 13,15
ST   D21S11: 29,33.2 (PubMed=25321415)
ST   D21S11: 29,33.2,34.2 (Millipore)
ST   D2S1338: 22,23
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 12
ST   D8S1179: 12,13
ST   FGA: 20,24
ST   Penta D: 11,12
ST   Penta E: 7,12
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C7700; Ovarian adenocarcinoma
DI   ORDO; Orphanet_213504; Adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 22
RX   PubMed=2910432; DOI=10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N;
RA   Geisinger K.R., Kute T.E., Pettenati M.J., Welander C.E., Dennard Y.,
RA   Collins L.A., Berens M.E.;
RT   "Characterization of a human ovarian carcinoma cell line with estrogen
RT   and progesterone receptors.";
RL   Cancer 63:280-288(1989).
RX   PubMed=9698466; DOI=10.1006/gyno.1998.5039;
RA   Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene is not a feature of
RT   ovarian cancers.";
RL   Gynecol. Oncol. 70:13-16(1998).
RX   PubMed=9769151; DOI=10.1007/s11626-996-0015-9;
RA   Baldwin W.S., Curtis S.W., Cauthen C.A., Risinger J.I., Korach K.S.,
RA   Barrett J.C.;
RT   "BG-1 ovarian cell line: an alternative model for examining
RT   estrogen-dependent growth in vitro.";
RL   In Vitro Cell. Dev. Biol. Anim. 34:649-654(1998).
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
RX   PubMed=25321415; DOI=10.1210/me.2014-1229;
RA   Li Y., Arao Y., Hall J.M., Burkett S.S., Liu L.-W., Gerrish K.,
RA   Cavailles V., Korach K.S.;
RT   "Research resource: STR DNA profile and gene expression comparisons of
RT   human BG-1 cells and a BG-1/MCF-7 clonal variant.";
RL   Mol. Endocrinol. 28:2072-2081(2014).